Laboratory diagnostics are essential tools of physician practice, informing many medical decisions. Physicians will increasingly rely on companion and other types of lab diagnostics that consider genetic, proteomic, or other markers in connection with drug treatment strategies.
Pain management is a problem for patients, practitioners, pharmacists, and others. Many patients are not getting the care and relief they deserve, even when they suffer from acute or chronic pain. In this blog post, Srinivas Nalamachu, MD asks if its possible to balance patient access to pain medication with safety and economic value.
Congressional standing to contest ACA insurance subsidies allowed but decision is in question
Brad Fluegel, chief healthcare commercial market development officer at Walgreens, discusses what managed care organizations and healthcare executives can learn from the success of retail clinics.
How will the increasing number of approvals for specialty medications affect managed care? Aimee Tharaldson, of Express Scripts, weighs in.
A new PwC report finds that most health system executives support the move away from fee-for-service (FFS), but struggle with how much they should invest in payment alternatives.
The CEO of Valeant Pharmaceuticals, which is being investigated by the government for raising drug prices, predicted more modest price increases ahead for the pharmaceutical industry.
Secukinumab may be an important new therapeutic treatment option for patients with psoriatic arthritis (PsA), according to a study published online in The New England Journal of Medicine.
Prescription opioid use disorders and deaths increased for the most recent 10 years tracked, even though the percentage of non-medical use of prescription opioids decreased, according to a new study.
The Comprehensive Care for Joint Replacement (CCJR), has organizations’ leadership wondering how they will be able to perform in such a model. Here are some tips.
Hospitals and physicians must be diligent in the implementation of their meaningful use business or strategic plan.
How plans can achieve the right balance between cost and outcomes
On October 6, 2015, the Centers for Medicare & Medicaid Services and Office of the National Coordinator for Health Information Technology released Meaningful Use-Stage 2 modifications and Stage 3 final rules.
Judge Rudolph Contreras ruled against the Department of Health and Human Services by saying that pharma companies do not have to offer rural and cancer hospitals that serve low-income populations 340B discounts on orphan drugs.
What managed care executives should know about rising drug prices, how they impact the healthcare system, and advice on what to do about it.
OptumRx program aims to ensure that optimal standards of quality are upheld by the pharmacies that produce and dispense them. Here's how the program works.
Researchers from the Department of Pharmaceutical Sciences at the State University of New York at Buffalo highlight efforts to promote safe and appropriate use of opioids.
In the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.
Five candidates in the campaign for the Democratic Party's presidential nomination took the stage October 13. Here are five key takeaways.
Traveling to Orlando for AMCP Nexus 2015? Make the most out of your trip by attending these presentations. View the top 10.
Raulo Frear, AMCP president, discusses the upcoming AMCP conference and some of the top challenges and opportunities facing the managed care pharmacy industry. Read more.
Partner with community-based organizations to implement quality diabetes programs for the Hispanic population.
Here are 3 major concerns patients with IPF should be aware of, according to research from Carlo Vancheri that appeared in a recent issue of Sarcoidosis Vasculitis and Diffuse Lung Diseases.
FDA has approved aripiprazole lauroxil (Aristada, Alkermes) extended-release injectable suspension for the treatment of adults with schizophrenia.
There is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.
Soon after the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC), it approved Opdivo (nivolumab) for an expanded use – to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
A new study by National Center for Policy Analysis (NCPA) finds that generic drugs are the best bargain in the healthcare system-but that may change if recent price hikes continue.